1. Home
  2. LOAN vs ATNM Comparison

LOAN vs ATNM Comparison

Compare LOAN & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.88

Market Cap

51.9M

Sector

Real Estate

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.51

Market Cap

50.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOAN
ATNM
Founded
1989
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.9M
50.2M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
LOAN
ATNM
Price
$4.88
$1.51
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
41.7K
206.8K
Earning Date
10-24-2025
11-14-2025
Dividend Yield
9.48%
N/A
EPS Growth
N/A
N/A
EPS
0.46
N/A
Revenue
$7,138,128.00
$90,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.47
$42,943.57
P/E Ratio
$10.48
N/A
Revenue Growth
N/A
11.11
52 Week Low
$4.29
$1.03
52 Week High
$6.05
$2.41

Technical Indicators

Market Signals
Indicator
LOAN
ATNM
Relative Strength Index (RSI) 55.96 59.46
Support Level $4.64 $1.37
Resistance Level $4.94 $1.54
Average True Range (ATR) 0.12 0.08
MACD 0.05 0.02
Stochastic Oscillator 88.79 82.35

Price Performance

Historical Comparison
LOAN
ATNM

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Share on Social Networks: